Organon & Co. OGN
Set alert
At close
Pre-market · Nov 3, 5:00 AM ET
- YTD
- +92.75%
- 1 year
- +105.96%
- Open
- 13.85
- Prev close
- 13.84
- Mkt cap
- 3.63B
- Vol
- 2.15M
- Avg vol
- 2.58M
- EPS
- 0.78
- P/E
- 17.72
- Div yield
- 0.58%
More statistics
- Low
- 13.82
- High
- 13.84
- Forward P/E
- 3.79
- Beta
- 1.49
- Short ratio
- 8.54
- Inst. own
- 84.58%
- Dividend
- 0.08
- Ex-div date
- Nov 8, 2026
- Earnings
- Feb 11, 2027
- 50-d avg
- 13.74
- 200-d avg
- 11.52
- 1y target
- 10.33
1m chart
Built from the cached one-day intraday bars.
Signals (92)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 3:55 PM | 15 hours ago |
| RSI: Overbought | Nov 2, 3:46 PM | 15 hours ago |
| MACD: Buy Signal | Nov 2, 3:18 PM | 16 hours ago |
| MACD: Sell Signal | Nov 2, 3:05 PM | 16 hours ago |
| MACD: Buy Signal | Nov 2, 3:04 PM | 16 hours ago |
| MACD: Sell Signal | Nov 2, 3:03 PM | 16 hours ago |
| MACD: Buy Signal | Nov 2, 3:02 PM | 16 hours ago |
| MACD: Sell Signal | Nov 2, 2:59 PM | 16 hours ago |
| MACD: Buy Signal | Nov 2, 2:58 PM | 16 hours ago |
| MACD: Sell Signal | Nov 2, 2:57 PM | 16 hours ago |
| MACD: Buy Signal | Nov 2, 2:51 PM | 16 hours ago |
| MACD: Sell Signal | Nov 2, 2:50 PM | 16 hours ago |
| MACD: Buy Signal | Nov 2, 2:44 PM | 17 hours ago |
| MACD: Sell Signal | Nov 2, 2:42 PM | 17 hours ago |
| MACD: Buy Signal | Nov 2, 2:41 PM | 17 hours ago |
| MACD: Sell Signal | Nov 2, 2:32 PM | 17 hours ago |
| MACD: Buy Signal | Nov 2, 2:24 PM | 17 hours ago |
| MACD: Sell Signal | Nov 2, 2:20 PM | 17 hours ago |
| MACD: Buy Signal | Nov 2, 2:19 PM | 17 hours ago |
| MACD: Sell Signal | Nov 2, 2:09 PM | 17 hours ago |
Newest 20 of 92.
Key statistics
- Market cap
- 3.63B
- Enterprise value
- 10.73B
- Trailing P/E
- 17.72
- Forward P/E
- 3.79
- PEG ratio
- 0.00
- Price / sales
- 0.60
- Price / book
- 3.04
- EPS (TTM)
- 0.78
- Beta
- 1.49
- Dividend yield
- 0.58%
- Payout ratio
- 10.26%
- Profit margin
- 3.49%
- Revenue (TTM)
- 6.10B
- Revenue growth
- -1.70%
- Free cash flow
- 721.37M
- Total cash
- 1.46B
- Total debt
- 8.55B
- Return on equity
- 20.29%
- Shares outstanding
- 262.62M
- Short % of float
- 8.14%
- 50-day average
- 13.74
- 200-day average
- 11.52
Analyst view
Consensus: hold
- Target (low)
- 8.00
- Target (mean)
- 10.33
- Target (high)
- 14.00
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell1
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate 0.94645.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | 0.92 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | 0.88 | 0.94 | +0.06 | +6.82% |
| Jul 31, 2026 | Jun 30, 2026 | 0.85 | 0.85 | 0.00 | 0.00% |
| Apr 30, 2026 | Mar 31, 2026 | 0.83 | 0.71 | -0.12 | -14.46% |
| Feb 12, 2026 | Dec 31, 2025 | 0.73 | 0.63 | -0.10 | -13.70% |
| Nov 10, 2025 | Sep 30, 2025 | 0.93 | 1.01 | +0.08 | +8.60% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 29, 2026 | BNP Paribas | down | Outperform | Neutral |
| Apr 28, 2026 | Piper Sandler | up | Underweight | Neutral |
| Feb 24, 2026 | Barclays | main | Underweight | Underweight |
| Dec 9, 2025 | Barclays | init | — | Underweight |
| Nov 11, 2025 | JP Morgan | main | Underweight | Underweight |
| Nov 11, 2025 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Organon & Co.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- organon.com
News
- Organon (OGN) Q3 Earnings and Revenues Top Estimates
- Organon Announces Quarterly Dividend
- Organon To Present Data From Its Current Phase 3 Trial Of MIUDELLA Intrauterine Device At 2026 Society Of Family Planning Annual Meeting
- Organon Canada Announces Availability Of NDUVRA To Treat Moderate To Severe Atopic Dermatitis
- This House of Representative Just Sold Up To $30K In Organon Stock
- Organon To Present Results From Post Hoc Analysis Of Pooled Data From Phase 3 Pivotal Trials, ADORING 1 And ADORING 2, Evaluating VTAMA Cream Versus Vehicle At 2026 SPD Annual Meeting
- Organon To Present Phase 3 Data Of VTAMA Cream In Atopic Dermatitis At 2026 Society For Pediatric Dermatology Annual Meeting
- Organon And Samsung Bioepis Expand Their Development And Commercialization Agreement To Provide OGN With Commercialization Rights In Canada To PYZCHIVA, Samsung Bioepis's Biosimilar Referencing STELARA
- Organon's Supplemental Biologics License Application Gets FDA Approval For TOFIDENCE To Treat Chimeric Antigen Receptor T Cell-Induced Severe Or Life-Threatening Cytokine Release Syndrome
- Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens Bankruptcy
Your note
Sign in to keep a note on OGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALI KEVIN | Chief Executive Officer | Purchase | May 4, 2025 | 282,731 |
| COX CARRIE SMITH | Officer and Director | Purchase | Nov 11, 2025 | 0 |
| FALCIONE AARON | Officer | Conversion of Exercise of derivative security | Mar 30, 2026 | 101,431 |
| HOLZBAUR LYNETTE | Officer | Purchase | May 5, 2026 | 52,850 |
| KARP DANIEL | Officer | Conversion of Exercise of derivative security | Mar 30, 2026 | 69,547 |
| MORRISSEY JOSEPH T JR | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 30, 2026 | 123,123 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.21% | 32,056,866 | 443.19M | Jun 29, 2026 |
| Pentwater Capital Management Lp | 6.89% | 18,100,000 | 250.23M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.76% | 15,132,118 | 209.20M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.54% | 11,909,865 | 164.65M | Jun 29, 2026 |
| State Street Corporation | 3.68% | 9,659,371 | 133.54M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 1.98% | 5,199,002 | 71.88M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 15,638,261 | 216.20M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 8,332,789 | 115.20M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 6,024,699 | 83.29M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.45% | 3,815,001 | 52.74M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.15% | 3,010,255 | 41.62M | Jun 29, 2026 |
| NexPoint Funds I-NexPoint Merger Arbitrage Fund | 1.03% | 2,705,080 | 37.40M | Jun 29, 2026 |
